logical development and expansion. The growing number of partnerships and collaborations between pharmaceutical companies and OOC manufacturers to develop high-throughput and scalable drug testing platforms to minimize financial losses due to late-stage drug failure has accelerated efforts to design and develop OOC platforms. It is pertinent to try to reproduce patient-specific tissues and organ systems in vitro and integrate them with high-throughput sensing platforms.This perspective highlights the most relevant advances in the last few years on biosensor integration in OOC platforms to achieve sensitive and realtime monitoring of metabolites and relevant biomarkers. The perspective also discusses potential challenges and opportunities to achieve clinically scalable, high-throughput multiorgan-on-achip systems with real-time monitoring using novel integrated imaging techniques and novel optical biosensors.